clinical trial · NCT04914247

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Actelion·—·approved for marketing

Non-healing WoundThromboangiitis ObliteransSelexipag

brief summary

The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.

started

—

primary completion

—

completion

—

last updated

Mar 27, 2026

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol